These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8295522)

  • 21. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 22. [The effect of desferrioxamine on the treatment of transfusion hemosiderosis--with special reference to the method of its administration (authors' transl)].
    Fujiyama N; Nakazawa K
    Rinsho Ketsueki; 1977 Dec; 18(12):1393-400. PubMed ID: 604522
    [No Abstract]   [Full Text] [Related]  

  • 23. [Subcutaneous administration of deferoxamine in a patient with panmyelopathy and post-transfusion hemosiderosis].
    Zdziarska B; Urasiński I
    Pol Arch Med Wewn; 1987 Jul; 78(1):48-51. PubMed ID: 3271285
    [No Abstract]   [Full Text] [Related]  

  • 24. [Disorders of iron metabolism in hereditary erythrocyte diseases].
    Levina AA; Andreeva AP; Nazarli AKh; Kudriavtseva LM; Tsibul'skaia MM
    Gematol Transfuziol; 1988 Jan; 33(1):11-5. PubMed ID: 3360275
    [No Abstract]   [Full Text] [Related]  

  • 25. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias.
    Wang WC; Ahmed N; Hanna M
    J Pediatr; 1986 Apr; 108(4):552-7. PubMed ID: 3083076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary haemochromatosis.
    Güngör T; Rohrbach E; Solem E; Kaltwasser JP; Kornhuber B
    Arch Dis Child; 1996 Apr; 74(4):323-7. PubMed ID: 8669933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y; Shaklai M; Liban E; Pinkhas J
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy of hemosiderosis with deferoxamine].
    Strohmeyer G; Stremmel W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1669-70. PubMed ID: 6489179
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
    Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.
    Inati A; Musallam KM; Wood JC; Taher AT
    Blood; 2010 Apr; 115(14):2980-1; author reply 2981-2. PubMed ID: 20378761
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of iron overload in children and adolescents on chronic haemodialysis.
    Eijgenraam FJ; Donckerwolcke RA
    Eur J Pediatr; 1990 Feb; 149(5):359-62. PubMed ID: 2311634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MR marrow signs of iron overload in transfusion-dependent patients with sickle cell disease.
    Levin TL; Sheth SS; Hurlet A; Comerci SC; Ruzal-Shapiro C; Piomelli S; Berdon WE
    Pediatr Radiol; 1995; 25(8):614-9. PubMed ID: 8570314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Congenital anemia].
    Graubner UB; Schmidt P; Haas RJ
    Internist (Berl); 1994 Mar; 35(3):269-74. PubMed ID: 8175291
    [No Abstract]   [Full Text] [Related]  

  • 34. [Continuous subcutaneous desferrioxamine infusions in patients with hemosiderosis (author's transl)].
    Tillmann W; König R; Schröder K; Schröter W
    Monatsschr Kinderheilkd; 1982 Mar; 130(3):171-2. PubMed ID: 7087975
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA; Green N; Flynn DM; Hoffbrand AV
    Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron chelation therapy in sickle cell anemia.
    Cohen A; Schwartz E
    Am J Hematol; 1979; 7(1):69-76. PubMed ID: 507048
    [No Abstract]   [Full Text] [Related]  

  • 37. Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.
    Reed W; Vichinsky EP
    J Pediatr Hematol Oncol; 2001 May; 23(4):197-202. PubMed ID: 11846294
    [No Abstract]   [Full Text] [Related]  

  • 38. Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.
    Yap J; O'Connor C; Kirby M; Guindi M; Roberts EA
    J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):382-5. PubMed ID: 19274798
    [No Abstract]   [Full Text] [Related]  

  • 39. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
    Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
    Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.